Inscripta Announces the First Commercial Shipment of Its Onyx™ Digital Genome Engineering Platform and Closes $150 Million in New Financing
By: Colorado BioScience Association Date: 04/05/2021
Inscripta, Inc., the digital genome engineering company, today announced the first commercial shipment of its Onyx™ platform and the closing of a $150 million Series E financing round led by Fidelity Management & Research Company LLC and funds and accounts advised by T. Rowe Price Associates, Inc.
Among the first organizations to receive the Onyx platform is GeneMill, a state-of-the-art synthetic biology foundry at the University of Liverpool. “Inscripta’s Onyx is an extraordinarily powerful platform that will enable high-throughput genome editing and analysis. It will revolutionize our abilities in synthetic biology,” said Professor Douglas Kell, Principal Investigator of the project funded under the Biotechnology & Biological Sciences Research Council’s ALERT 19 competition.
Dr. James Johnson, lead co-applicant and head of the Liverpool GeneMill, added, “We look forward to continuing our close collaboration with the Inscripta team, working together to explore a wide range of genome discovery and forward-engineering research projects with our customers and collaborators from around the world.”
In a 2020 report, the McKinsey Global Institute estimated that 60% of physical inputs used in manufacturing today could one day be produced through biological means. Plastics, fuels, medicines, and more could be made via sustainable, planet-friendly biological pipelines such as yeast fermentation. Already, yeast is being used to produce sweeteners, industrial chemicals, and medicinal components.
Find out more in the Inscripta press release.